Term
| best marker for insulin release |
|
Definition
|
|
Term
| pathogenesis of microvascular cpx in DM |
|
Definition
| glycosylation causes trapping of LDL in vessel walls, oxidizing LDL |
|
|
Term
|
Definition
|
|
Term
|
Definition
1. NS
2. IV insulin bolus (15u)
3. IV insulin drip
4. D5 when sugar gets to 250
5. monitor K+ and Phos
6. d/c insulin drip when anion gap closes and/or patient is hungry; won't b hungry in the presence of ketones |
|
|
Term
|
Definition
| dilate efferent arterioles decreasing pressure inside bowman's capsule; prevents proteinuria |
|
|
Term
| presentation of 3rd nerve palsy (common in DM) |
|
Definition
| diplopia/ptosis with pupilary reflex intact |
|
|
Term
|
Definition
1. TCAs
2. Neurontin (gaba)
3. Lyrica (pregabalin)
4. Cymbalta (duloxetine)
5. anticonvulsants |
|
|
Term
| which ear pathology do you worry about in DM |
|
Definition
| malignant otitis externa; pseudomonas = hospitalize |
|
|
Term
| sulfonylureas: MOA and examples |
|
Definition
| stimulate pancrease to release insulin; glyburide, glipizide, chlorpropamide |
|
|
Term
| sulfonylurea that can cause SIADH |
|
Definition
|
|
Term
|
Definition
Aka: glucophage
MOA: increase insulin sensitivity
SE: Lactic acidosis, renal insuf |
|
|
Term
| Glucosidase inhibitors: MOA, SE, examples |
|
Definition
|
|
Term
|
Definition
| precose, glucosidase inhibitor |
|
|
Term
|
Definition
aka: Glyset
class: glucosidase inhibitor |
|
|
Term
| repaglinide: AKA, class, MOA |
|
Definition
AKA: prandin
class: meglitinide
MOA: < pp glu |
|
|
Term
|
Definition
AKA: starlix
MOA: < pp glu |
|
|
Term
| exenatide: AKA, MOA, Class |
|
Definition
AKA: byetta
MOA: increases pp insulin release (wt loss)
Class: GLP-1 agonist |
|
|
Term
| sitagliptin: AKA, CLass, MOA, SE |
|
Definition
AKA: januvia
class: DPP-4 inhibitor
MOA:inhibit glucagon release
SE: pancreatitis, GI |
|
|
Term
| Rx that < pp glu for TIIDM |
|
Definition
1. glucosidase inhibitors: acarbose, miglitol (inhibit glu absorption)
2. repaglinide
3. nateglenide |
|
|
Term
| thiazolinediones: 2, MOA, SE, CIs |
|
Definition
2: pio and rosiglitazone
MOA: enhance GLUT receptors
SE: Liver
CIs: in CHF esp if on insulin |
|
|
Term
| ACEi and Statins rec for which diabetics |
|
Definition
|
|
Term
|
Definition
| insulin causing hypogly in the middle of the night and rebound hypergly in the am |
|
|
Term
|
Definition
| GH in the am causes glu to rise |
|
|
